Bibliography
- Carsen PE , FlanaganCL, IokesCE: Enzymatic deficiency in primaquine-sensitive erythrocytes.Science124, 484–485 (1956).
- Kalow W , StaronN: On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers.Can. J. Med. Sci.35, 1305–1320 (1957).
- Gonzalez FJ , SkodaRC, KimuraS et al.: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.Nature331, 442–446 (1988).
- Rogers JF , NafzigerAN, BertinoJS Jr: Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med.113, 746–750 (2002).
- Mahgoub A , IdleJR, DringLG: Polymorphic hydroxylation of debrisoquine in man.Lancet2(8038), 584–586 (1977).
- Eichelbaum M , BertilssonL, SaweJ, Zekorn C: Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin. Pharmacol. Ther.31, 184–186 (1982).
- Dahl ML , IseliusL, AlmC et al. : Polymorphic 2-hydroxylation of desipramine. A population and family study. Eur. J. Clin. Pharmacol.44, 445–450 (1993).
- Johansson I , LundqvistE, BertilssonL, Dahl ML, Sjoqvist F, Ingelman-Sundberg M: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA90, 11825–11829 (1993).
- Fagerlund TH , BraatenO: No pain relief from codeine? An introduction to pharmacogenomics.Acta Anaesthesiol. Scand.45, 140–149 (2001).
- Stamer UM , LehnenK, HothkerF, WolfS, HoeftA: Impact of CYP2D6 on postoperative tramadol analgesia.Pain105, 231–238 (2003).
- Chow MS , WhiteCM, LauCP: Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation.J. Clin. Pharmacol.41, 92–96 (2001).
- Floyd MD , GervasiniG, MasicaAL et al. : Genotype–phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European– and African–American men and women. Pharmacogenetics13, 595–606 (2003).
- Kuehl P , ZhangJ, LinY: Sequence diversity in CYP3A promoters and characterization of the genetic basis for polymorphic CYP3A5 expression.Nat. Genet.27, 383–391 (2001).
- Wong M , BalleineRL, CollinsM, LiddleC, ClarkeCL, GurneyH: CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.Clin. Pharmacol. Ther.75, 529–538 (2004).
- Kidd RS , StraughnAB, MeyerMC: Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.Pharmacogenetics9,71–80 (1999).
- Blaisdell J , MohrenweiserH, JacksonJ et al.: Identification and functional characterization of new potentially defective alleles of human CYP2C19.Pharmacogenetics12, 703–711 (2002).
- Lockridge O , MassonP: Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk.Neurotoxicol. 21,113–126 (2000).
- Ostergaard D , JensenFS, JensenE, SkovgaardLT, Viby-MogensenJ: Mivacurium induced neuromuscular blockade in patients with atypical plasma cholinesterase.Acta Anaesthesiol. Scand.37, 314–318 (1993).
- Petersen RS , BaileyPL, KalameghanR, AshwoodER: Prolonged neuromuscular block after mivacurium.Anesthesiol.76, 194–196 (1993).
- Rosenberg MK , Lebenbom-MansourM: Markedly prolonged paralysis after mivacurium in a patient apparently heterzygous for the atypial and usual pseudocholinesterase alleles by conventional biochemical testing.Anesth. Analg.84, 457–460 (1998).
- Gatke MR , Viby-MogensenJ, Ostergaard D, Budgaard JR: Response to mivacurium in patients carrying the K variant in the butyrylcholinesterase gene. Anesthesiol.102, 503–508 (2005).
- Ceppa F , GidenneS, BenoisA, FontanE, BurnatP: Rapid identification of atypical variant of plasma butyrylcholinesterase by PCR.Clin. Chem. Lab. Med.40,799–801 (2002).
- Butcher NJ , BoukouvalaS, SimE, Minchin RF: Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenom. J.2, 30–42 (2002).
- Cascorbi I , DrakoulisN, BrockmollerJ, MaurerA, SperlingK, RootsI: Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.Am. J. Hum. Genet.57, 581–592 (1995).
- Clark DW : Genetically determined variability in acetylation and oxidation. Therapeutic implications.Drugs29,342–375 (1985).
- Spielberg SP : N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.J. Pharmacokinet. Biopharm.24, 509–519 (1996).
- Brinkmann U , RootsI, EichelbaumM: Pharmacogenetics of the human drug transporter gene MDR1: impact of polymorphisms on pharmacotherapy.Drug Discov. Today6,835–839 (2001).
- Hoffmeyer S , BurkO, von Richter O et al.: Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97, 3473–3478 (2000).
- Ishikawa T , TsujiA, Inui K-I et al.: The genetic polymorphism of drug transporters: functional anlaysis approaches. Pharmacogenomics5,67–99 (2004).
- Brini M : Ryanodine receptor defects in muscle genetic diseases.Biochem. Biophys. Res. Commun.322, 1245–1255 (2004).
- Lötsch J , GeisslingerG: Are µ-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol. Med.11, 82–89 (2005).
- Uhl GR , SoraI, WangZ: The μ-opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses.Proc. Natl Acad. Sci. USA96, 7752–7755 (1999).
- Caraco Y : Variability in alfentanil analgesia may be attributed to polymorphism in the μ-opiod receptor gene.Clin. Pharmacol. Ther.69, 63 (2001).
- Klepstad P , RakvagTT, KaasaS et al.: The 118A>G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.Acta Anaesthesiol. Scand.48, 1232–1239 (2004).
- Romberg R , OlofsenE, SartonE, den HartighJ, TaschnerPE, DahanA: Pharmacokinetic–pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences.Anesthesiology100, 120–133 (2004).
- Lötsch J , SkarkeC, GroschS, DarimontJ, SchmidtH, GeisslingerG: The polymorphism A118G of the human μ-opioid receptor gene decreases the clinical activity of morphine-6-glucuronide but not that of morphine.Pharmacogenetics12, 3–9 (2002).
- Skarke C , DarimontJ, SchmidtH, GeisslingerG, LotschJ: Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers.Clin. Pharmacol. Ther.73, 107–121 (2003).
- Romberg RR , OlofsenE, BijlH et al.: Polymorphism of µ-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response.Anesthesiology102(3), 522-530 (2005).
- Koch T , SchulzS, PfeifferM et al.: C-terminal splice variants of the mouse µ-opioid receptor differ in morphine-induced internalization and receptor resensitization.J. Biol Chem.276, 31408–31414 (2001).
- Befort K , FilliolD, DecaillotFM, Gaveriaux-RuffC, HoeheMR, KiefferBL: A single nucleotide polymorphic mutation in the human µ-opioid receptor severely impairs receptor signalling.J. Biol. Chem.276, 3130–3137 (2001).
- Koch T , KroslakT, MayerP, RaulfE, Hollt V: Site mutation in the rat µ-opioid receptor demonstrates the involvement of calcium/calmodulindependent protein kinase II in agonist-mediated desensitization. J. Neurochem.69, 1767–1770 (1997).
- Xu K , LiuXH, NagarajanS, GuXY, GoldmanD: Relationship of the δ-opioid receptor gene to heroin abuse in a large Chinese case/control sample.Am. J. Med. Genet.110, 45–50 (2002).
- Niemi G , BreivikH: The minimally effective concentration of adrenalinee in a low-concentration thoracic epidural analgesic infusion of bupivacaine, fentanyl and adrenalinee after major surgery – a randomized, double-blind, dose-finding study.Acta Anes. Scand.47, 439–450 (2003).
- Steiner H , GerfenCR: Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior.Exp. Brain. Res.123, 60–67 (1998).
- Chen JF , AloyoVJ, WeissB: Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases µ opioid receptors in mouse striatum.Neuroscience54, 669–680 (1993).
- Lotta T , VidgrenJ, TilgmannC, UlmanenI, MelenK, JulkunenI, TaskinenJ: Kinetics of human soluble and membrane bound catechol O-methyltransferase: a revised mechanism and description of the termolabile varient of the enzyme.Biochemistry34,4202–4210 (1995).
- Zubieta JK , HeitzegMM, SmithYR et al.: COMT val158met genotype affects mu-opioid neurotransmitter response to a pain stressor.Science299, 1240–1243 (2003).
- Rakvåg TT , KlepstadP, BaarC et al.: The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients.Pain116,73–78 (2005).
- Belelli I , PistisI, PetersJA, LambertJJ: General anaesthetic action at transmitter-gated inhibitory amino acid receptors.Trends Pharmacol. Sci.20, 496–502 (1999).
- Chou IC , PengCT, HuangCC, TsaiJJ, Tsai FJ, Tsai CH: Association analysis of γ 2 subunit of γ-aminobutyric acid type A receptor polymorphisms with febrile seizures. Pediatr. Res.54, 26–29 (2003).
- Vaquero C , Baca-GarciaE, Diaz-SastreC et al.: New GABAA receptor α5 subunit gene polymorphism that may confound genotyping. Am. J. Med. Genet. B Neuropsychiatr. Genet.129, 27–28 (2004)
- Lappalainen J , KrupitskyE, RemizovM et al.: Association between alcoholism and γ-amino butyric acid α2 receptor subtype in a Russian population. Alcohol Clin.Exp. Res.29, 493–498 (2005)
- Joo A , ShibataH, NinomiyaH, Kawasaki H, Tashiro N, Fukumaki Y: Structure and polymorphisms of the human metabotropic glutamate receptor Type 2 gene (GRM2): analysis of association with schizophrenia. Mol. Psych.6, 186–192 (2001).
- Siest G , BertrandP, HerbethB et al.:. Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin. Chem. Lab. Med.38,841–852 (2000).
- Kertai MD , BoersmaE, KleinJ, van Urk H, Poldermans D: Optimising the prediction of perioperative mortality in vascular surgery by using a customized probability model. Arch. Intern. Med.165, 898–904 (2005).
- Xing Y , SonnerJM, EgerEI, CascioM, SesslerDI: Mice with a melanocortin-1 receptor mutation have slightly greater MAC than control mice.Anesthesiology101, 544–546 (2004).
- Liem EB , Lin C-M, Suleman M-I et al.: Increased anesthetic requirement in redheads. Anesthesiology101,279–283 (2004).
- Liem EB , JoinerTV, TsuedaK, SesslerDI: Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficay in redheads.Anesthesiology102, 509–514 (2005).
- Urwyler A , DuefelT, McCarthyT, WestS: A protocol of the investigation of malignant hyperpyrexia susceptibility.Br. J. Anaesth.86,283–287 (2001).
- Sweeney BP : Do genes influence the outcome from anaesthesia? Br. J. Anaesth.90,725–727 (2003).
- Schwinn DA , BoothJV: Genetics infuses new life into human physiology: implications of the human genome project for anesthesiology and perioperative medicine.Anesthesiology962, 61–63 (2002).
- Bukaveckas BL , ValdesR Jr, Linder MW: Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia. J. Cardiothorac. Vasc. Anesth.18, 353–365 (2004).